Keywords: xoma, start, raptiva, trial, psoriatic, arthritis, partner

Xoma to start Raptiva trial in psoriatic arthritis

Article | 10 February 2003

Print This

Xoma and partner Genentech have initiated a Phase II trial of itsICAM-1 blocker Raptiva (efalizumab) in patients with active and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in